Literature DB >> 15479437

Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides.

Karen White1, Philip Kearns, Istvan Toth, Sarah Hook.   

Abstract

A problem facing the use of subunit peptide and protein vaccines is their inability to stimulate protective immune responses. Many different approaches have been utilized to overcome this inefficient immune activation. The approach we have taken is to modify the vaccine antigen so that it now has adjuvant properties. To do this, multiple copies of minimal CD8 T cell epitopes were attached to a poly lysine lipid core. These constructs are known as lipid-core-peptides (LCP). The research presented here examines the adjuvant activity of LCP. Using mouse models, we were able to show that LCP were indeed able to activate antigen-presenting cells in vitro and to activate cytotoxic T-cell responses in vivo. More importantly, LCP were able to stimulate the development of a protective antitumour immune response. Copyright 2004 Australasian Society for Immunology Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479437     DOI: 10.1111/j.0818-9641.2004.01269.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  4 in total

1.  Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.

Authors:  Karen White; Thomas Rades; Philip Kearns; Istvan Toth; Sarah Hook
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 2.  Supramolecular peptide vaccines: tuning adaptive immunity.

Authors:  Yi Wen; Joel H Collier
Journal:  Curr Opin Immunol       Date:  2015-07-08       Impact factor: 7.486

3.  Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model.

Authors:  Simon H Apte; Penny L Groves; Mariusz Skwarczynski; Yoshio Fujita; Chenghung Chang; Istvan Toth; Denise L Doolan
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

4.  A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect.

Authors:  Yuting Yang; Xiaowei Tai; Kairong Shi; Shaobo Ruan; Yue Qiu; Zhirong Zhang; Bing Xiang; Qin He
Journal:  Theranostics       Date:  2016-09-12       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.